Insights

Clinical-stage Partnering IO Biotech is a clinical-stage biopharma focused on immune-modulatory cancer vaccines with lead candidate Cylembio in clinical trials. Potential sales opportunity: explore collaboration or licensing agreements with vaccine manufacturing partners, larger biotech, or pharma companies seeking immune-oncology platforms to expand their oncology portfolio.

Expanded Financing The company has raised substantial funding ($256M) and secured a EUR 57.5M debt facility from the EIB, indicating strong financial backing. Sales potential lies in offering strategic value-add services, ecosystem partnerships, or co-development financing arrangements to de-risk clinical programs for potential offerors.

Global Footprint Headquartered in Copenhagen with US HQ in New York suggests a transatlantic commercialization and collaboration pathway. Sales opportunities include cross-border manufacturing, clinical trial services, regulatory affairs support, and regional partnering deals to leverage both EU and US markets.

Immuno-oncology Focus T-win platform aims to activate T cells to target tumors and suppressive microenvironments. This aligns with buyers seeking next-gen immunotherapies; potential BD targets include CROs with IO trial networks, adjuvant vaccine developers, and companies seeking to augment existing IO portfolios.

Competitive Landscape Recent news notes departures of senior leadership and competitive mentions with Moderna, indicating a dynamic startup environment. A sales angle could emphasize agility, specialized vaccine programs, and opportunities to provide advisory, outsourced GMP manufacturing, or strategic advisory services to sustain momentum in a competitive space.

Similar companies to IO Biotech

IO Biotech Tech Stack

IO Biotech uses 8 technology products and services including Joomla, RSS, WordPress, and more. Explore IO Biotech's tech stack below.

Media & News

IO Biotech's Email Address Formats

IO Biotech uses at least 4 email formats:
IO Biotech Email FormatsExamplePercentage
LF@iobiotech.comDJ@iobiotech.com
37%
FL@iobiotech.comJD@iobiotech.com
32%
First.Last@iobiotech.comJohn.Doe@iobiotech.com
17%
Last@iobiotech.comDoe@iobiotech.com
14%

Frequently Asked Questions

What is IO Biotech's stock symbol?

Minus sign iconPlus sign icon
IO Biotech is a publicly traded company; the company's stock symbol is IOBT.

What is IO Biotech's official website and social media links?

Minus sign iconPlus sign icon
IO Biotech's official website is iobiotech.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does IO Biotech generate?

Minus sign iconPlus sign icon
As of October 2026, IO Biotech's annual revenue is estimated to be $1M - $10M.

What is IO Biotech's SIC code and NAICS code?

Minus sign iconPlus sign icon
IO Biotech's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does IO Biotech have currently?

Minus sign iconPlus sign icon
As of October 2026, IO Biotech has approximately 30 employees across 3 continents, including Europe, North America and Asia. Key team members include Chief Executive Officer And Founder: M. Z., Chief Scientific Officer: M. A. and Vice President Clinical Development: F. R. Explore IO Biotech's employee directory with LeadIQ.

What industry does IO Biotech belong to?

Minus sign iconPlus sign icon
IO Biotech operates in the Biotechnology Research industry.

What technology does IO Biotech use?

Minus sign iconPlus sign icon
IO Biotech's tech stack includes Joomla, RSS, WordPress, Microsoft 365, Modernizr, Sendinblue, DocuSign and WP Engine.

What is IO Biotech's email format?

Minus sign iconPlus sign icon
IO Biotech's email format typically follows the pattern of LF@iobiotech.com. Find more IO Biotech email formats with LeadIQ.

How much funding has IO Biotech raised to date?

Minus sign iconPlus sign icon
As of October 2026, IO Biotech has raised $256M in funding. The last funding round occurred on Jan 20, 2025 for $60M.

When was IO Biotech founded?

Minus sign iconPlus sign icon
IO Biotech was founded in 2015.
IO Biotech logo

IO Biotech

Biotechnology ResearchHovedstaden, Denmark11-50 Employees

IO Biotech is a clinical-stage biotechnology company focused on developing immune-modulating, off-the-shelf therapeutic cancer vaccines using its T-win platform. The T-win platform is designed to activate T cells to attack both tumor cells and immune-suppressive cells in the tumor microenvironment. Its lead cancer vaccine candidate, Cylembio, is in clinical trials, while additional vaccine candidates are advancing through preclinical development. Headquartered in Copenhagen, Denmark, IO Biotech also maintains a US headquarters in New York and employs between 11 and 50 people. The company has pursued public financing, completing an initial public offering in 2021.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
IOBT
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
11-50

Section iconFunding & Financials

  • $256M

    IO Biotech has raised a total of $256M of funding over 8 rounds. Their latest funding round was raised on Jan 20, 2025 in the amount of $60M as a Post IPO Debt.

  • $1M - $10M

    IO Biotech's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.